Patient characteristics
|
Gender: Female
|
16 (44 %)
|
9 (31 %)
|
0.269
|
Age ≥55 years
|
24 (67 %)
|
11 (38 %)
|
0.021
|
Hospital admission within previous 12 months
|
21 (58 %)
|
11 (38 %)
|
0.102
|
Hospital-acquired infection
|
10 (28 %)
|
12 (41 %)
|
0.249
|
Previous MRSA infection or colonization
|
8 (22 %)
|
5 (17 %)
|
0.618
|
Positive influenza test
|
1 (3 %)
|
2 (7 %)
|
0.582
|
Post-infection length of stay: median (IQR), in daysa
|
6 (2–18)
|
12 (4–24)
|
0.232
|
Charlson Comorbidity Index score: median (IQR)
|
2 (1–3)
|
2 (0–4)
|
0.778
|
30-day mortalityb
|
11 (31 %)
|
4 (14 %)
|
0.111
|
Antimicrobial prescribed
|
Linezolid
|
11 (31 %)
|
2 (7 %)
|
0.018
|
Vancomycin
|
33 (92 %)
|
29 (100 %)
|
0.247
|
Microbial characteristics
|
agr dysfunction
|
8 (22 %)
|
4 (14 %)
|
0.384
|
Toxic shock syndrome toxin-1
|
1 (3 %)
|
0 (0 %)
|
1.000
|
hVISA
|
1 (3 %)
|
0 (0 %)
|
1.000
|
Arginine catabolic mobile element
|
1 (3 %)
|
23 (79 %)
|
<0.001
|
Panton-Valentine leukocidin
|
0 (0 %)
|
26 (90 %)
|
<0.001
|
SCCmec
|
Type II
|
35 (97 %)
|
4 (14 %)
|
<0.001
|
Type IV
|
0 (0 %)
|
25 (86 %)
|
<0.001
|